Status:
UNKNOWN
Anti Xa Monitoring Low Molecular Weight Heparin on Prevention of Venous Thromboembolism
Lead Sponsor:
Xuanwu Hospital, Beijing
Collaborating Sponsors:
Peking University First Hospital
Conditions:
Venous Thromboembolism
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism, is a common cardiovascular disease associated with significant morbidity ranging from painful leg swelli...
Detailed Description
Low molecular weight heparins (LMWH) are commonly used injectable anticoagulants for venous thromboembolism (VTE) prophylaxis and treatment. LMWH forms an inhibitory complex with antithrombin to inact...
Eligibility Criteria
Inclusion
- Aged 18 years or older
- No gender limited
- Prospectively screened for risk and included if they received LMWH
- The patient or his / her legal representative is able and willing to sign the informed consent
Exclusion
- History of hemorrhage or high risk of hemorrhage, including subarachnoid hemorrhage, cerebral hemorrhage, traumatic brain injury, blood system diseases, etc
- Severe renal insufficiency before randomization (creatinine clearance rate (CCr) \< 30mL/min)
- Expected length of ICU stay less than 3 days
- Known to be allergic to LMWH
- Pregnancy
- History of heparin induced thrombocytopenia
- Patients with iliac vein compression syndrome
- Receive non LMWH for prevention VTE according to the physician
Key Trial Info
Start Date :
May 16 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
858 Patients enrolled
Trial Details
Trial ID
NCT05382481
Start Date
May 16 2022
End Date
December 31 2024
Last Update
April 5 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100053